AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Pluri Inc. Report Publication Announcement 2017

Oct 26, 2017

6990_rns_2017-10-26_72a9faa0-2a6f-4e1e-a8f8-c3244c1ed1a4.htm

Report Publication Announcement

Opens in your device viewer

_________ false


��	2 381
PLURISTEM THERAPEUTICS INC
Corporation no: C12337-2001	8544
- - -


	Israel Securities Authority			Tel Aviv Stock Exchange		C003 ( Public )		Reported via MAGNA:	26/10/2017
	www.isa.gov.il			www.tase.co.il				Reference:	2017-02-094228	Time of broadcast: 13:55 13:48:02

Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


	The corporation is a foreign private issuer as defined by U.S. Securities Laws.


Attached hereto is a report on	Following Approval of Israel�s Ministry of Health, Pluristem Extends its Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery after Bone Marrow Transplant and Opens Clinical Centers in Israel

MOH_Approval_for_PLX-R18_Phase_I_Trial_final_isa.pdf



References of previous documents relating to this matter(the reference does not constitute incorporation by reference):


- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 25/09/2017
Address: Matam Park 5 , Haifa 31905 ISRAEL , Tel: 074-7107171 , Fax: 074-7107172
E-mail address: [email protected] Company site: www.pluristem.com

Previous names of reporting entity:

Name of the Signatory: Aberman Zalman Position of Signatory in the reporting corporation: Chairman Of The Board & CEO Name of Employer Company:
Address: Matam Park 20 , Haifa 31905 Telephone: 074-7107171 Facsimile: 074-7107172 E-mail: [email protected] 2